Trials / Completed
CompletedNCT02969525
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 206 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | |
| DRUG | Bimekizumab | Bimekizumab in different dosage regimens. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-11-01
- Completion
- 2018-07-01
- First posted
- 2016-11-21
- Last updated
- 2023-03-20
- Results posted
- 2020-11-25
Locations
40 sites across 6 countries: United States, Czechia, Germany, Hungary, Poland, Russia
Source: ClinicalTrials.gov record NCT02969525. Inclusion in this directory is not an endorsement.